MindRank AI Secures $52 Million in Series B Funding
MindRank AI, a Hangzhou-based biotechnology company, has announced the closing of a $52 million Series B funding round. The company operates a comprehensive, AI-powered platform aimed at revolutionizing small molecule drug discovery. This funding round was supported by a consortium of institutional and healthcare funds.
Advancing AI-Driven Drug Discovery
MindRank AI is focused on developing an AI-native engine that integrates multiple scientific disciplines including biology, chemistry, and computation to facilitate innovative drug research and development. The company's proprietary platform, known as the Molecule Arts Platform (MAP), is designed to unify these fields into a cohesive research and development system.
The newly secured funds will be instrumental in furthering the capabilities of MAP, as well as advancing MindRank's diverse clinical and preclinical pipeline. A key focus of this pipeline is the company's lead program, MDR-001, an oral small-molecule GLP-1 receptor agonist, which is currently undergoing Phase III clinical trials in China. This program has progressed from its inception to Phase III in about 4.5 years, with a cumulative R&D investment of approximately $23 million.
Clinical and Preclinical Developments
Beyond MDR-001, MindRank AI has achieved three Investigational New Drug (IND) clearances in both China and the United States, and has nominated five additional candidates for preclinical development. These developments highlight the versatility and effectiveness of the company's Molecule Arts Platform in accelerating drug discovery processes.
Strategic Use of Funds
The $52 million raised in this Series B round will be allocated primarily towards enhancing the capabilities of the Molecule Arts Platform and supporting the advancement of MindRank's clinical and preclinical drug candidates. With this strategic funding, MindRank AI aims to continue its mission to transform the landscape of drug discovery through its innovative AI-driven approaches.
This Series B funding marks a significant milestone for MindRank AI as it continues to leverage its AI-powered platform to discover and develop new medicines. The support from institutional and healthcare investors underscores the potential of MindRank's approach in the competitive field of biotechnology.